RxDoctor Payments Data

Rebecca Odorizzi, DO

Family Medicine · Tamaqua, PANPI 1932167020

Payments from drug & device makers

$1,598in general payments, 2019–2025

Across 85 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$265
  • Mannkind Corporation$164
  • Boehringer Ingelheim$159
  • Amgen$137
  • Abbott$131
  • Merck$114
  • plus $627 from 15 others

What the payments were for

  • Food & beverage$1,57999%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,598 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$76,149
Medicare patients
247
Services billed
1,312

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin110$125,784
OzempicSemaglutide83$95,331
EliquisApixaban79$79,016
Trelegy ElliptaFluticasone/Umeclidin/Vilanter50$44,891
JanuviaSitagliptin Phosphate33$40,913
XareltoRivaroxaban26$29,088
LinzessLinaclotide20$25,176
Breo ElliptaFluticasone/Vilanterol39$17,113
MounjaroTirzepatide11$11,942
TrulicityDulaglutide11$10,580
Trijardy XrEmpaglifloz/Linaglip/Metformin12$7,216
Spiriva RespimatTiotropium Bromide12$6,081
Albuterol Sulfate HfaAlbuterol Sulfate161$5,223
Gabapentin194$4,059
Atorvastatin Calcium415$3,787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr, Spiriva Respimat$159$139,081134 claims
Novo NordiskOzempic$265$95,33183 claims
GSKTrelegy Ellipta, Breo Ellipta$69$62,00489 claims
MerckJanuvia$114$40,91333 claims
AbbVieLinzess, Synthroid, Armour Thyroid$30$29,21989 claims
Johnson & JohnsonXarelto$29$29,08826 claims
Lilly USA, LLCMounjaro, Trulicity$53$22,52222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Tamaqua

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →